# Targeting Monocytes and Their Derivatives in Ovarian Cancer: Opportunities for Innovation in Prognosis and Therapy

## TL;DR

This review discusses how monocytes and their derivatives influence ovarian cancer and how targeting them could improve diagnosis and treatment.

## Contribution

The paper highlights new therapeutic and prognostic opportunities by focusing on monocytes and their role in ovarian cancer.

## Key findings

- Monocytes and their derivatives contribute to immune suppression and chemoresistance in ovarian cancer.
- Strategies like TAM reprogramming and DC vaccines show promise in restoring anti-tumour immunity.
- Monocyte-to-lymphocyte ratios are emerging as cost-effective prognostic tools for ovarian cancer.

## Abstract

Ovarian cancer is a serious disease that is often discovered at an advanced stage with limited treatment options and modest outcomes. This review explores the role of immune cells, mainly monocytes and their derivatives, which can either fight cancer or help it grow. This review also highlights how these cells contribute to ovarian cancer development and how they might be targeted to improve treatment outcomes. We also discuss the imbalance between different immune cells, and this may help predict the disease progression and patient outcomes. By understanding how monocytes and their related cells influence ovarian cancer, researchers and clinicians may be able to design better diagnostic tools and more effective personalised therapies in the future.

Ovarian cancer remains the most lethal gynaecological malignancy primarily due to late-stage diagnosis, high recurrence rate, and limited treatment efficacy. Current diagnostic tools, including imaging and serum markers, lack sufficient sensitivity and specificity for early detection. Increasing evidence highlights the critical role of myeloid-derived immune cells within the tumour microenvironment in shaping ovarian cancer progression and therapy response. Monocytes and their derivatives are central regulators of immune suppression, chemoresistance, and metastatic dissemination in ovarian tumours. Their recruitment and polarisation are governed by several signalling pathways offering promising therapeutic targets. Strategies including monocyte depletion, TAM reprogramming, MDSC maturation, DC vaccines, and their synergistic use with chemotherapy or immune checkpoint inhibitors are being explored to restore anti-tumour immunity in ovarian cancer. Parallel to therapeutic potential, the lymphocyte-to-monocyte ratio and its reciprocal monocyte-to-lymphocyte ratio have also emerged as potential accessible and cost-effective prognostic tools that predict disease aggressiveness and survival in ovarian cancer. This review features the diagnostic, prognostic, and therapeutic significance of monocytes and their derivatives in ovarian cancer management and highlighting new opportunities for next-generation immunomodulatory therapies.